What an incredible few days at Jefferies & London Life Science Week! 🎉 A huge thank you to Jefferies, the BioIndustry Association (BIA), MedCity, and London & Partners for hosting this goliath event. It gets bigger, better and more impactful every year, and we’re proud to be part of it. We are glad so many […]
You have probably already seen the news: not one but two major European life science funds have closed in the last week – collectively raising a massive €1.15 billion! Last Friday (November 14), leading European life sciences venture capital firm Medicxi announced it had closed its €500 million Medicxi V fund. And on Monday, (November […]
Differentiated profile of ALY-301 designed to enable chronic dosing in mast cell dependent diseases while avoiding the safety limitations of conventional c-Kit inhibitors Multicenter Phase 1/1b study to enroll both healthy volunteers and patients with Cold Urticaria with initial data readouts expected in 2026 Boston, Massachusetts and Lausanne, Switzerland, 30 October 2025 – Alys Pharmaceuticals, […]
Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications ALY-101 is formulated as an intradermal injectable for the treatment of Alopecia Areata Health Authorities in Canada and the United States provided swift CTA & IND approval allowing for efficient dosing of the first patients Boston, Massachusetts and […]
ALY-101 is an intradermal injectable JAK1 siRNA-lipid conjugate for the treatment of Alopecia Areata Significant progress made in advancing the Alys pipeline following $100m seed financing from Medicxi Boston, Massachusetts and Lausanne, Switzerland, 4th February 2025 – Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces that the U.S. Food and Drug Administration (FDA) […]
